PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1965283
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1965283
The plasma fractionation market is poised for substantial growth as demand rises for plasma derived therapies used in treating immune deficiencies, bleeding disorders, neurological conditions, and other chronic diseases. According to the latest PS Market Research forecast, the market is expected to expand from USD 37.0 billion in 2025 to USD 61.6 billion by 2032, registering a CAGR of approximately 7.6% during 2026-2032. Expansion in plasma collection infrastructure, broader adoption of immunoglobulins and other plasma derivatives, and advances in purification and chromatography techniques are key drivers of this growth. A rising prevalence of rare diseases requiring lifelong plasma based therapies and increasing regulatory approvals for plasma derived products are further reinforcing market dynamics.
Key Insights
Market Structure: The global plasma fractionation market is consolidated, with a few major multinational companies holding significant share due to extensive plasma collection networks, high capital requirements, and decades of expertise in plasma protein production.
Product Trends: Immunoglobulins account for the largest market share in 2025, driven by broad clinical use in immunology and neurology, while coagulation factors are the fastest growing product segment due to rising therapeutic applications.
Technology Adoption: Ion exchange chromatography holds the largest share among fractionation technologies due to its efficiency and ability to support the production of high purity therapeutics. Affinity chromatography is the fastest growing technological category, enabling enhanced protein separation and yield.
Application Insights: The neurology segment dominates due to extensive use of immunoglobulins for conditions such as chronic inflammatory demyelinating polyneuropathy and Guillain Barre syndrome, while oncology is forecast to be the fastest growing application driven by increasing therapy use in cancer related immunodeficiency.
End Users: Hospitals & clinics hold the largest share in 2025, reflecting their role as primary administration sites for intravenous and other plasma derived therapies requiring clinical oversight.
Regional Leaders: North America is the largest regional market due to well established plasma donation and fractionation infrastructure, strong R&D activity, and high healthcare expenditure, while Asia Pacific is the fastest growing region driven by expanding healthcare access and rising plasma collection capacities.
Growth Drivers: Aging demographics, rising prevalence of rare and chronic diseases requiring plasma derived treatments, and expanding regulatory approvals for new products are key factors propelling market growth.
Innovation Trends: Technological advancements such as improved chromatography and purification systems are boosting processing efficiency, increasing therapeutic yields, and expanding product portfolios across key players.